FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2201609171> ?p ?o ?g. }

• W2201609171 abstract "Biologicals are critical in cancer medicine. Four of the top ten biological blockbusters worldwide are oncology drugs used for therapeutic or supportive care. The global market for biologic cancer therapies approximately totalled US$ 51.2 billion in 2014 and is expected to reach US$ 66.4 billion in 2019. The patents of most of these top-selling agents will expire by the year 2020 attracting industry to develop biosimilars - agents with high similarity to their biological reference product. Furthermore, manufacturing biosimilars is more cost and time effective than developing their reference products. The cost containments derived from the biosimilars entry to the market are expected to result in considerable societal savings and financial relief to health systems globally. Led by the European Medicines Agency, and the Food and Drug Administration, several other regulatory agencies continue to develop their approval and pharmacovigilance (PV) programs for biosimilars worldwide. Maximizing the safety monitoring and reporting of adverse events (AEs) associated with biosimilars will be critical to rapidly find a place in cancer medicine. Greater efforts to educate patients and healthcare providers to report AEs as well as requesting periodical dissemination and publication of reports by sponsors will be determinant to ensure the post-marketing safety of these agents and gaining the trust of health care providers. This article reviews common and postmarketing AEs associated with the three top cancer biologicals with upcoming expiration patents, their reported AEs during post-marketing surveillance and discusses potential challenges in the PV process of cancer biosimilars." @default.
• W2201609171 created "2016-06-24" @default.
• W2201609171 creator A5011465880 @default.
• W2201609171 creator A5019330820 @default.
• W2201609171 date "2016-01-01" @default.
• W2201609171 modified "2023-09-28" @default.
• W2201609171 title "Pharmacovigilance of Oncology Biosimilars" @default.
• W2201609171 cites W1963939974 @default.
• W2201609171 cites W1984854090 @default.
• W2201609171 cites W1989250261 @default.
• W2201609171 cites W1999475844 @default.
• W2201609171 cites W2002997762 @default.
• W2201609171 cites W2004824444 @default.
• W2201609171 cites W2005848612 @default.
• W2201609171 cites W2006174096 @default.
• W2201609171 cites W2010086949 @default.
• W2201609171 cites W2031889731 @default.
• W2201609171 cites W2059162723 @default.
• W2201609171 cites W2064671306 @default.
• W2201609171 cites W2078702709 @default.
• W2201609171 cites W2088332148 @default.
• W2201609171 cites W2097995306 @default.
• W2201609171 cites W2101090208 @default.
• W2201609171 cites W2102537627 @default.
• W2201609171 cites W2104177162 @default.
• W2201609171 cites W2105436256 @default.
• W2201609171 cites W2119740605 @default.
• W2201609171 cites W2139366207 @default.
• W2201609171 cites W2144794315 @default.
• W2201609171 cites W2145137957 @default.
• W2201609171 cites W2149904628 @default.
• W2201609171 cites W2153918851 @default.
• W2201609171 cites W2158946535 @default.
• W2201609171 cites W2169560977 @default.
• W2201609171 cites W2314290920 @default.
• W2201609171 doi "https://doi.org/10.4172/2329-6887.s3-001" @default.
• W2201609171 hasPublicationYear "2016" @default.
• W2201609171 type Work @default.
• W2201609171 sameAs 2201609171 @default.
• W2201609171 citedByCount "8" @default.
• W2201609171 countsByYear W22016091712016 @default.
• W2201609171 countsByYear W22016091712017 @default.
• W2201609171 countsByYear W22016091712021 @default.
• W2201609171 crossrefType "journal-article" @default.
• W2201609171 hasAuthorship W2201609171A5011465880 @default.
• W2201609171 hasAuthorship W2201609171A5019330820 @default.
• W2201609171 hasConcept C126322002 @default.
• W2201609171 hasConcept C142724271 @default.
• W2201609171 hasConcept C144133560 @default.
• W2201609171 hasConcept C160735492 @default.
• W2201609171 hasConcept C162324750 @default.
• W2201609171 hasConcept C162853370 @default.
• W2201609171 hasConcept C197636746 @default.
• W2201609171 hasConcept C197934379 @default.
• W2201609171 hasConcept C204787440 @default.
• W2201609171 hasConcept C2524010 @default.
• W2201609171 hasConcept C2777436895 @default.
• W2201609171 hasConcept C2780035454 @default.
• W2201609171 hasConcept C33923547 @default.
• W2201609171 hasConcept C50522688 @default.
• W2201609171 hasConcept C57658597 @default.
• W2201609171 hasConcept C59491497 @default.
• W2201609171 hasConcept C71924100 @default.
• W2201609171 hasConcept C90673727 @default.
• W2201609171 hasConcept C98274493 @default.
• W2201609171 hasConceptScore W2201609171C126322002 @default.
• W2201609171 hasConceptScore W2201609171C142724271 @default.
• W2201609171 hasConceptScore W2201609171C144133560 @default.
• W2201609171 hasConceptScore W2201609171C160735492 @default.
• W2201609171 hasConceptScore W2201609171C162324750 @default.
• W2201609171 hasConceptScore W2201609171C162853370 @default.
• W2201609171 hasConceptScore W2201609171C197636746 @default.
• W2201609171 hasConceptScore W2201609171C197934379 @default.
• W2201609171 hasConceptScore W2201609171C204787440 @default.
• W2201609171 hasConceptScore W2201609171C2524010 @default.
• W2201609171 hasConceptScore W2201609171C2777436895 @default.
• W2201609171 hasConceptScore W2201609171C2780035454 @default.
• W2201609171 hasConceptScore W2201609171C33923547 @default.
• W2201609171 hasConceptScore W2201609171C50522688 @default.
• W2201609171 hasConceptScore W2201609171C57658597 @default.
• W2201609171 hasConceptScore W2201609171C59491497 @default.
• W2201609171 hasConceptScore W2201609171C71924100 @default.
• W2201609171 hasConceptScore W2201609171C90673727 @default.
• W2201609171 hasConceptScore W2201609171C98274493 @default.
• W2201609171 hasLocation W22016091711 @default.
• W2201609171 hasOpenAccess W2201609171 @default.
• W2201609171 hasPrimaryLocation W22016091711 @default.
• W2201609171 hasRelatedWork W2009070247 @default.
• W2201609171 hasRelatedWork W2089190513 @default.
• W2201609171 hasRelatedWork W2139366207 @default.
• W2201609171 hasRelatedWork W2180859504 @default.
• W2201609171 hasRelatedWork W2274594750 @default.
• W2201609171 hasRelatedWork W2461702436 @default.
• W2201609171 hasRelatedWork W2610819809 @default.
• W2201609171 hasRelatedWork W2617588020 @default.
• W2201609171 hasRelatedWork W2623157416 @default.
• W2201609171 hasRelatedWork W2890461594 @default.
• W2201609171 hasRelatedWork W2903505135 @default.
• W2201609171 hasRelatedWork W2950336427 @default.
• W2201609171 hasRelatedWork W2956392898 @default.

• next